Pharmacy Benefit Management

From Specialty Pharmacy News - It’s not only the United States that’s seeing costs to treat cancer continue to rise. Last year the cost of cancer drugs and supportive therapies totaled $107 billion globally, an 11.5% increase in constant dollars from 2014, according to a new report from the IMS Institute for Healthcare Informatics. That’s up from an annual cost growth rate of 3.8% in 2011, according to the report, titled Global Oncology Trend Report: A Review of 2015 and Outlook to 2020. In the U.S., the annual growth rate for cancer drug costs rose from 2.0% in 2011 to 13.9% last year. Read more

From Drug Benefit News - As the roles of retail pharmacies are set to transform, PBMs can capitalize on their own capabilities and collaborate with pharmacies, as well as other stakeholders, in a variety of ways. Pharmacies, maintains a recently released report, have the opportunity to offer a wide array of services from which consumers can pick and choose. This could be done through broadening their own offerings, as well as collaborating with other health… Read more

Pharmacy Benefit Management Blog

By Lauren Flynn Kelly - April 14, 2016
In the latest squabble between drugstores and PBMs, the National Community Pharmacists Association (NCPA) on April 1 issued a letter to CMS Deputy Director Cynthia Tudor asserting that Medicare Part D plans and PBMs are not complying with a federal requirement to use drug pricing standards that “...
By Angela Maas - March 30, 2016
As high drug prices continue to make headlines and draw congressional ire, hepatitis C drugs and “Mr. Wu-Tang” Martin Shkreli seem to be getting a reprieve as focus turns to the prostate cancer drug Xtandi. On March 28, 12 members of Congress sent a letter to HHS Sec. Sylvia Burwell and Francis...
By Lauren Flynn Kelly - March 4, 2016
Since the introduction of direct-acting antivirals that in clinical trials demonstrated higher sustained virologic response (SVR) rates in hepatitis C patients than ever before, we’ve seen figures on sales, treatment costs, adherence levels, etc. For example, Harvoni (ledipasvir and sofosbuvir) and...

It's quick and easy to sign up for FREE access to!

Why do I need to register?